Skip to main content

Post-Traumatic Headache

7
Pipeline Programs
11
Companies
14
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 10 programs with unclassified modality

On Market (2)

Approved therapies currently available

PRAZOSIN HYDROCHLORIDEApproved
prazosin
Unknown Company
oral2024
Eli Lilly and Company
EMGALITYApproved
galcanezumab-gnlm
Eli Lilly and Company
injection2018

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
Galcanezumab-GnlmPHASE_4
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
AbobotulinumtoxinAPhase 41 trial
Active Trials
NCT03928496Completed40Est. Feb 2017
Prevail Therapeutics
1 program
1
Galcanezumab-GnlmPhase 41 trial
Active Trials
NCT06901518Completed25Est. Nov 2024
Sound Pharmaceuticals
1 program
1
PrazosinPhase 41 trial
Active Trials
NCT02965027Completed89Est. Jun 2023
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
sumatriptan/naproxen sodiumPhase 41 trial
Active Trials
NCT01053507Terminated23Est. Nov 2012
Sandoz
SandozAustria - Kundl
1 program
1
AMG 334Phase 21 trial
Active Trials
NCT03974360Completed100Est. Dec 2019
Genomics
GenomicsUK - Oxford
2 programs
Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic HeadacheN/A1 trial
ErenumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT04369729Completed101Est. Aug 2025
NCT04098250Completed6Est. Jan 2024
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic HeadacheN/A
electroCore
electroCoreNJ - Rockaway
1 program
gammaCore SapphireN/A1 trial
Active Trials
NCT04071743Withdrawn0Est. Dec 2021
Teva
TevaIsrael - Petach Tikva
1 program
FremanezumabPHASE_2Monoclonal Antibody5 trials
Active Trials
NCT04041284Completed353Est. Aug 2022
NCT03347188Completed87Est. Jun 2020
NCT03107052Terminated275Est. Jun 2019
+2 more trials
Ipsen
IpsenChina - Tianjin
1 program
AbobotulinumtoxinAPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Prevail TherapeuticsGalcanezumab-Gnlm
TevaFremanezumab
Sound PharmaceuticalsPrazosin
Angeles TherapeuticsAbobotulinumtoxinA
ViiV Healthcaresumatriptan/naproxen sodium
TevaFremanezumab
TevaFremanezumab
TevaFremanezumab
TevaFremanezumab
GenomicsErenumab
SandozAMG 334
TevaFremanezumab
GenomicsInvestigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
electroCoregammaCore Sapphire

Clinical Trials (14)

Total enrollment: 4,288 patients across 14 trials

NCT06901518Prevail TherapeuticsGalcanezumab-Gnlm

The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches

Start: Aug 2020Est. completion: Nov 202425 patients
Phase 4Completed
NCT04041284TevaFremanezumab

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Start: Sep 2019Est. completion: Aug 2022353 patients
Phase 4Completed
NCT02965027Sound PharmaceuticalsPrazosin

Prazosin for Post-Concussive Headaches

Start: Nov 2016Est. completion: Jun 202389 patients
Phase 4Completed
NCT03928496Angeles TherapeuticsAbobotulinumtoxinA

Abobotulinumtoxina Efficacy in Post-Traumatic Headache

Start: Aug 2013Est. completion: Feb 201740 patients
Phase 4Completed
NCT01053507ViiV Healthcaresumatriptan/naproxen sodium

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

Start: May 2010Est. completion: Nov 201223 patients
Phase 4Terminated
NCT03107052TevaFremanezumab

A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache

Start: Apr 2017Est. completion: Jun 2019275 patients
Phase 3Terminated
NCT02945046TevaFremanezumab

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

Start: Jan 2017Est. completion: May 2019169 patients
Phase 3Terminated
NCT02621931TevaFremanezumab

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Start: Mar 2016Est. completion: Apr 20171,130 patients
Phase 3Completed
NCT02638103TevaFremanezumab

Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

Start: Feb 2016Est. completion: Dec 20181,890 patients
Phase 3Completed
NCT04098250GenomicsErenumab

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH

Start: Jan 2021Est. completion: Jan 20246 patients
Phase 2Completed
NCT03974360SandozAMG 334

Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache

Start: Apr 2019Est. completion: Dec 2019100 patients
Phase 2Completed
NCT03347188TevaFremanezumab

A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)

Start: Dec 2017Est. completion: Jun 202087 patients
Phase 2Completed
NCT04369729GenomicsInvestigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Start: Sep 2020Est. completion: Aug 2025101 patients
N/ACompleted
NCT04071743electroCoregammaCore Sapphire

Study of Gammacore Sapphire for the Acute and Preventive Treatment of Post-Traumatic Headache (GAP-PTH)

Start: Jan 2020Est. completion: Dec 20210
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.